Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.

Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4 pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4 inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism of CDK4 inhibitors, the structure activity relationships (SARs) of the selective CDK4 inhibitors and the latest developments of the selective CDK4 inhibitors in clinical trials. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Citation

Haixing Guan, Yongli Du, Weiwei Han, Jingkang Shen, Qunyi Li. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies. Anti-cancer agents in medicinal chemistry. 2017;17(5):646-657

Mesh Tags

Substances

PMID: 28044938

search → result